Madrigal Pharmaceuticals is under investigation after a whistleblower complaint from a former senior executive accused the company of suppressing adverse safety data and presenting unreliable efficacy results for its drug Rezdiffra. The allegations include manipulation of clinical outcomes by an unblinded board member. Following the disclosure, Madrigal's stock price fell over 8%. Investors who suffered losses may have legal rights under federal securities laws, with a law firm offering to assist affected shareholders.
Madrigal Pharmaceuticals investigation news is provided here with Pluang's Health sector market data as context. As of Nov 07, 2026 07:41 WIB, among 150 priced Health-sector US stocks tradable on Pluang, 87 rose and 63 fell. Notable movers include Ginkgo Bioworks Holdings Inc (DNA) at USD 11.39 with a 14.36% increase, Summit Therapeutics Inc (SMMT) at USD 16.22 with a 14.31% increase, and Globus Medical Inc. Class A Common Stock (GMED) at USD 71.30 with a 12.54% decrease. The highest one-day change recorded is +14.36%.
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
Coinbase experienced a significant net outflow of 83.7 million Tether (USDT) tokens within a single hour. This movement highlights notable activity in the digital asset market on the platform. While USDT is designed to maintain a 1-to-1 peg with the ...
As of November 5, Bitcoin's 12-month return has trailed gold's for 365 consecutive days, marking a rare occurrence previously seen in 2014-2015 and 2022-2023. Historically, after such periods, Bitcoin experienced significant annualized compound growt...
Ethereum saw nearly $300 million in long position liquidations recently, but the price dropped just over 1%, indicating limited selling pressure. A trader with a strong winning record has opened a large long position, suggesting confidence in a poten...
DraftKings lowered its full-year 2026 revenue guidance on November 6, 2026, to $6.35 billion-$6.55 billion, down from the previous $6.5 billion-$6.9 billion range set three months earlier. The revision is mainly due to increased investment in its Pre...
